Astellas Pharma
Logotype for Astellas Pharma Inc

Astellas Pharma (4503) investor relations material

Astellas Pharma Investor presentation summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Astellas Pharma Inc
Investor presentation summary17 Nov, 2026

Q2 YTD performance and FY2026 outlook

  • Q2 YTD revenue rose 23% YoY and core operating profit rose 50%, driven by Strategic Brands growth and cost optimization.

  • FY2026 forecast raised to ¥2,330B revenue and ¥700B core operating profit, with a 30.0% core operating margin.

  • Strategic Brands FY2026 sales forecast increased by ¥70B to ¥680B; FY2026 SG&A forecast is ¥815B and R&D expense is ¥360B.

  • Q2 YTD Strategic Brands sales reached ¥333.9B, up 51% YoY; PADCEV sales were ¥158.3B, up 55%.

  • XTANDI Q2 YTD sales were ¥533.7B, up 12% YoY; sales are expected to decline in 2H due to the US IRA impact.

Growth strategy and profitability targets

  • FY2026 revenue forecast is ¥2.3T; the outlook targets a pipeline-led inflection from FY2029 and record-high revenue in the mid-2030s.

  • Strategic Brands target 2x FY2025 sales by FY2030; PADCEV, IZERVAY, VYLOY, VEOZAH and XOSPATA are the portfolio’s growth brands.

  • Strategic Brands are projected to exceed 50% of revenue by FY2030, while core operating profit plus R&D is targeted at 50% of revenue.

  • CSP2026 deliverables include ¥4.3T+ cumulative core operating profit before R&D expense and core operating profit before R&D at 50% of revenue.

Pipeline development

  • FY2026–30 plans call for 10+ Phase 3 or pivotal study starts, including 5+ by FY2027; pipeline revenue potential is ~¥1T in the mid-2030s.

  • Pipeline assets are expected to drive growth from FY2029 onward, with R&D base spending averaging 20% of revenue and additional investment of up to 5%.

  • Setidegrasib Phase 3 studies are ongoing in 1L pancreatic cancer and 2L+ NSCLC, with primary analyses anticipated in FY2029 and FY2028, respectively.

  • ASP2138 is in a Phase 3 1L gastric/GEJ study; Phase 1 data showed 62.5% unconfirmed ORR in 1L and responses across low-intermediate and high CLDN18.2 expression.

  • VIR-5500 Phase 1 data in heavily pretreated mCRPC showed 45% ORR among RECIST-evaluable patients; FDA Fast Track designation was granted.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Astellas Pharma earnings date

Logotype for Astellas Pharma Inc
Q3 20273 Feb, 2027
Astellas Pharma
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Astellas Pharma earnings date

Logotype for Astellas Pharma Inc
Q3 20273 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Astellas Pharma Inc., is a Japanese multinational pharmaceutical company that emerged from the merger between Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. in 2005. Astellas focuses on several key therapeutic areas including oncology, urology, immunology, cardiology, and infectious diseases, with a priority on research and development in infectious diseases, diabetes, gastrointestinal diseases, oncology, and central nervous system diseases. Astellas Pharma Inc. is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.